19-Norandrostenedione refers to two steroid isomers that were once marketed as dietary supplements and mainly used by body builders. After 2005, 19-Norandrostenedione was regulated in the United States as a schedule III controlled substance, as well as banned from use in competitive sports by the World Anti-Doping Agency.
In the body 19-norandrostenedione is rapidly metabolized into nandrolone, also known as nortestosterone.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Flunisolide | The risk or severity of edema formation can be increased when 19-norandrostenedione is combined with Flunisolide. |
| Beclomethasone dipropionate | The risk or severity of edema formation can be increased when 19-norandrostenedione is combined with Beclomethasone dipropionate. |
| Betamethasone | The risk or severity of edema formation can be increased when 19-norandrostenedione is combined with Betamethasone. |
| Fluticasone propionate | The risk or severity of edema formation can be increased when 19-norandrostenedione is combined with Fluticasone propionate. |
| Fluocinolone acetonide | The risk or severity of edema formation can be increased when 19-norandrostenedione is combined with Fluocinolone acetonide. |
| Triamcinolone | The risk or severity of edema formation can be increased when 19-norandrostenedione is combined with Triamcinolone. |
| Prednisone | The risk or severity of edema formation can be increased when 19-norandrostenedione is combined with Prednisone. |
| Fludrocortisone | The risk or severity of edema formation can be increased when 19-norandrostenedione is combined with Fludrocortisone. |
| Hydrocortisone | The risk or severity of edema formation can be increased when 19-norandrostenedione is combined with Hydrocortisone. |
| Prednisolone | The risk or severity of edema formation can be increased when 19-norandrostenedione is combined with Prednisolone. |
| Methylprednisolone | The risk or severity of edema formation can be increased when 19-norandrostenedione is combined with Methylprednisolone. |
| Trilostane | The risk or severity of edema formation can be increased when 19-norandrostenedione is combined with Trilostane. |
| Budesonide | The risk or severity of edema formation can be increased when 19-norandrostenedione is combined with Budesonide. |
| Dexamethasone | The risk or severity of edema formation can be increased when 19-norandrostenedione is combined with Dexamethasone. |
| Corticotropin | The risk or severity of edema formation can be increased when 19-norandrostenedione is combined with Corticotropin. |
| Cortisone acetate | The risk or severity of edema formation can be increased when 19-norandrostenedione is combined with Cortisone acetate. |
| Paramethasone | The risk or severity of edema formation can be increased when 19-norandrostenedione is combined with Paramethasone. |
| Ciclesonide | The risk or severity of edema formation can be increased when 19-norandrostenedione is combined with Ciclesonide. |
| Aldosterone | The risk or severity of edema formation can be increased when 19-norandrostenedione is combined with Aldosterone. |
| Fluticasone furoate | The risk or severity of edema formation can be increased when 19-norandrostenedione is combined with Fluticasone furoate. |
| Fluprednidene | The risk or severity of edema formation can be increased when 19-norandrostenedione is combined with Fluprednidene. |
| Tixocortol | The risk or severity of edema formation can be increased when 19-norandrostenedione is combined with Tixocortol. |
| Fluprednisolone | The risk or severity of edema formation can be increased when 19-norandrostenedione is combined with Fluprednisolone. |
| Meprednisone | The risk or severity of edema formation can be increased when 19-norandrostenedione is combined with Meprednisone. |
| Dexamethasone isonicotinate | The risk or severity of edema formation can be increased when 19-norandrostenedione is combined with Dexamethasone isonicotinate. |
| Melengestrol | The risk or severity of edema formation can be increased when 19-norandrostenedione is combined with Melengestrol. |
| Deflazacort | The risk or severity of edema formation can be increased when 19-norandrostenedione is combined with Deflazacort. |
| Cortivazol | The risk or severity of edema formation can be increased when 19-norandrostenedione is combined with Cortivazol. |
| Prednylidene | The risk or severity of edema formation can be increased when 19-norandrostenedione is combined with Prednylidene. |
| Fluocortin | The risk or severity of edema formation can be increased when 19-norandrostenedione is combined with Fluocortin. |
| Fluperolone | The risk or severity of edema formation can be increased when 19-norandrostenedione is combined with Fluperolone. |
| Cloprednol | The risk or severity of edema formation can be increased when 19-norandrostenedione is combined with Cloprednol. |
| Fluclorolone | The risk or severity of edema formation can be increased when 19-norandrostenedione is combined with Fluclorolone. |
| Fluticasone | The risk or severity of edema formation can be increased when 19-norandrostenedione is combined with Fluticasone. |
| Mometasone furoate | The risk or severity of edema formation can be increased when 19-norandrostenedione is combined with Mometasone furoate. |
| Hydrocortisone acetate | The risk or severity of edema formation can be increased when 19-norandrostenedione is combined with Hydrocortisone acetate. |
| Hydrocortisone cypionate | The risk or severity of edema formation can be increased when 19-norandrostenedione is combined with Hydrocortisone cypionate. |
| Hydrocortisone succinate | The risk or severity of edema formation can be increased when 19-norandrostenedione is combined with Hydrocortisone succinate. |
| Prednisolone phosphate | The risk or severity of edema formation can be increased when 19-norandrostenedione is combined with Prednisolone phosphate. |
| Prednisolone hemisuccinate | The risk or severity of edema formation can be increased when 19-norandrostenedione is combined with Prednisolone hemisuccinate. |
| Methylprednisolone hemisuccinate | The risk or severity of edema formation can be increased when 19-norandrostenedione is combined with Methylprednisolone hemisuccinate. |
| Prednisone acetate | The risk or severity of edema formation can be increased when 19-norandrostenedione is combined with Prednisone acetate. |
| Clocortolone acetate | The risk or severity of edema formation can be increased when 19-norandrostenedione is combined with Clocortolone acetate. |
| Melengestrol acetate | The risk or severity of edema formation can be increased when 19-norandrostenedione is combined with Melengestrol acetate. |
| Betamethasone phosphate | The risk or severity of edema formation can be increased when 19-norandrostenedione is combined with Betamethasone phosphate. |
| Cortisone | The risk or severity of edema formation can be increased when 19-norandrostenedione is combined with Cortisone. |
| Clobetasol propionate | The risk or severity of edema formation can be increased when 19-norandrostenedione is combined with Clobetasol propionate. |
| Fluocinonide | The risk or severity of edema formation can be increased when 19-norandrostenedione is combined with Fluocinonide. |
| Hydrocortisone butyrate | The risk or severity of edema formation can be increased when 19-norandrostenedione is combined with Hydrocortisone butyrate. |
| Desoximetasone | The risk or severity of edema formation can be increased when 19-norandrostenedione is combined with Desoximetasone. |
| Mometasone | The risk or severity of edema formation can be increased when 19-norandrostenedione is combined with Mometasone. |
| Fluocortolone | The risk or severity of edema formation can be increased when 19-norandrostenedione is combined with Fluocortolone. |
| Prednisolone acetate | The risk or severity of edema formation can be increased when 19-norandrostenedione is combined with Prednisolone acetate. |
| Fluorometholone | The risk or severity of edema formation can be increased when 19-norandrostenedione is combined with Fluorometholone. |
| Difluocortolone | The risk or severity of edema formation can be increased when 19-norandrostenedione is combined with Difluocortolone. |
| Flumethasone | The risk or severity of edema formation can be increased when 19-norandrostenedione is combined with Flumethasone. |
| Methylprednisolone aceponate | The risk or severity of edema formation can be increased when 19-norandrostenedione is combined with Methylprednisolone aceponate. |
| Dexamethasone acetate | The risk or severity of edema formation can be increased when 19-norandrostenedione is combined with Dexamethasone acetate. |
| Corticotropin zinc hydroxide | The risk or severity of edema formation can be increased when 19-norandrostenedione is combined with Corticotropin zinc hydroxide. |
| Fluocortolone pivalate | The risk or severity of edema formation can be increased when 19-norandrostenedione is combined with Fluocortolone pivalate. |
| Fluocortolone caproate | The risk or severity of edema formation can be increased when 19-norandrostenedione is combined with Fluocortolone caproate. |
| Desoxycortone | The risk or severity of edema formation can be increased when 19-norandrostenedione is combined with Desoxycortone. |
| Vamorolone | The risk or severity of edema formation can be increased when 19-norandrostenedione is combined with Vamorolone. |